Dopamine‐Related Genotypes and Physical Activity Change During an Intervention: The Lifestyle Interventions and Independence for Elders Study by Rosso, Andrea L. et al.
Dopamine-Related Genotypes and Physical Activity Change
During an Intervention: The Lifestyle Interventions and
Independence for Elders Study
Andrea L. Rosso, MPH, PhD,* Andrea L. Metti, MPH, PhD,* Nancy W. Glynn, PhD,*
Robert M. Boudreau, PhD,* W. Jack Rejeski, PhD,† Nicolaas Bohnen, MD, PhD,‡§
Haiying Chen, PhD,¶ Neil M. Johannsen, PhD,k Abby C. King, PhD,** Todd M. Manini, PhD,††
Marco Pahor, MD,†† Stephanie A. Studenski, MD, MPH,‡‡ Carlos A. Vaz Fragoso, MD,§§
Caterina Rosano, MD, MPH,* and for the LIFE Study Group
OBJECTIVES: To determine whether intervention-induced
physical activity (PA) changes in sedentary older adults
differed according to dopamine-related genotype.
DESIGN: Randomized clinical trial (Lifestyle Interventions
and Independence for Elders Trial (2010–13)).
SETTING: Multicenter study, 8 U.S. locations.
PARTICIPANTS: Volunteer sample of sedentary adults
aged 70 to 89 at risk of disability (N51635).
INTERVENTIONS: Structured PA versus health educa-
tion (HE) for an average of 2.6 years.
MEASUREMENTS: Single-nucleotide polymorphisms of
dopamine-related genes (dopamine receptor (DR) D1,
DRD2, DRD3, and catechol-O-methyltransferase
(COMT)) were assessed. Average moderate to vigorous
PA (MVPA) was calculated using accelerometry (min/d) at
baseline and 6, 12, and 24 months. Between-arm MVPA
differences according to genotype and genotype with
square root–transformed MVPA separately according to
arm were tested, stratified according to race, and adjusted
for multiple comparisons.
RESULTS: White participants in the PA arm (n5513) had
higher average square root transformed MVPA
(4.9161.91)than those in the HE arm (n5538)
(4.5161.82) (p5.001). Between-arm differences were
greater for DRD2 Met/Met (high dopamine; HE:
4.7661.80, PA: 5.5361.60, p5.03) than Val/Val (low
dopamine; HE: 4.5861.92, PA: 4.8161.83, p5.16);
results were similar for COMT. In the PA arm, DRD2
Met/Met was associated with higher average MVPA
(5.3962.00) than Met/Val (4.4662.51) (p5.01) and Val/
Val (4.6562.71) (p5.01). There were no associations for
other genes. Associations were not significant in blacks
but followed similar trends.
CONCLUSION: Higher dopamine signaling may support
changes in PA during an intervention. The role of
dopamine-related pathways in promoting PA participation
and enhancing response to interventions in sedentary older
adults should be studied.
TRIAL REGISTRATION: clinicaltrials.gov Identifier:
NCT01072500 J Am Geriatr Soc 66:1172–1179, 2018.
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Physical activity (PA) has well-documented benefits forolder adults, including lower risk of disability1 and
dementia,2 but physical inactivity and sedentary behavior
are common, with only 8.5% of adults aged 60 to 69 and
6.3% of those aged 70 and older meeting the recom-
mended 150 min/wk of PA.3 Even with intervention-
induced increases, PA levels typically wane over time.1
Identification of phenotypes and mechanisms that explain
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low response to PA interventions may improve promotion
efforts.
It has been theorized that dopamine plays a role in
PA participation.4,5 Cerebral dopaminergic function regu-
lates factors related to PA in older adults,6 including cog-
nitive control,7 physical function,8 motivation and reward
response,9 and depressive mood.10 Several genes regulate
dopaminergic neurotransmission, and polymorphisms in
these genes have functional and behavioral consequen-
ces.7,11,12 These genes include those related to dopamine
receptor density (dopamine receptor (DR) D1, DRD2,
DRD3) and metabolism (catechol-O-methyltransferase
(COMT)). Prior observational studies have largely found
no associations between these genes and self-reported PA
across the lifespan,13–16 but associations with changes in
PA during structured interventions have not been studied.
We tested associations between DR and COMT poly-
morphisms and changes in objectively measured PA in the
Lifestyle Interventions and Independence for Elders (LIFE)
randomized controlled study. LIFE tested a 2-year struc-
tured PA intervention for prevention of mobility disability
in at-risk older adults. We hypothesized that genotypes
related to higher dopamine function would be associated
with greater increases in PA than genotypes related to
lower dopamine function. We further explored individual
characteristics that might explain associations between
dopamine-related genotypes and PA, including changes in
physical and cognitive function and mood.
METHODS
Study population
Details of the LIFE study are provided elsewhere.1,17 Par-
ticipants were recruited18 at 8 centers across the United
States (University of Florida, Gainesville and Jacksonville,
Florida; Northwestern University, Chicago, Illinois; Pen-
nington Biomedical Research Center, Baton Rouge, Louisi-
ana; University of Pittsburgh, Pittsburgh, Pennsylvania;
Stanford University, Stanford, California; Tufts University,
Boston, Massachusetts; Wake Forest School of Medicine,
Winston-Salem, North Carolina; Yale University, New
Haven, Connecticut). Participants were eligible if they
were aged 70 to 89, were sedentary (reporting <20 min/
wk regular PA in past month), had a Short Physical Per-
formance Battery (SPPB)19 score of 9 or less, were able to
walk 400 m in less than 15 minutes without assistance,
had no major cognitive impairment, and could safely par-
ticipate in a walking-based PA intervention; 1,635 partici-
pants were randomized (818 to PA, 817 to health
education (HE)) between February 2010 and December
2011. Institutional review boards at all institutions
approved the study, and all participants provided written
informed consent.
Participants were excluded from analyses if they did
not have accelerometer data at baseline and at least 2
additional time points (n5231), if they did not self-
identify as black or white (n5108), or if they were missing
genotype data (n5262); categories not mutually exclusive.
Genotypes were randomly distributed according to inter-
vention arm (Supplemental Table S1). Our analytical
sample was less likely to be female (p5.02) or black
(p<.001) and had higher baseline Modified Mini-Mental
State Examination (3MS) scores (p<.001), faster 400-m
walk time (p5.001), and higher percentage session attend-
ance for the duration of the intervention (68.4% vs
40.7%; p<.001) than those excluded. They did not differ
on other characteristics, including change in functional
measures (all p>.11).
Participant flow is shown in Supplemental Figure S1.
Interventions
The active intervention period was 24 to 42 months (aver-
age 31 months), with the end point for these analyses at
24 months.
The PA intervention consisted of walking (goal of
150 min/wk) and strength, flexibility, and balance train-
ing.17 Participants attended 2 center-based visits per
week and were instructed to complete home-based activ-
ities 3 to 4 times per week. The intervention was person-
alized, with a target of 30 min/d of moderate intensity
walking.
The HE program consisted of weekly workshops on
successful aging for the first 26 weeks, followed by
monthly sessions. The workshops did not include PA rec-
ommendations but included light upper extremity stretch-
ing and flexibility exercises.
Independent Variable—Dopamine Genotypes
Deoxyribonucleic acid samples were genotyped using Taq-
Man allelic discrimination (Life Technologies/Fisher Scien-
tific, Foster City, CA). Polymerase chain reaction primers
and probes for COMT single-nucleotide polymorphism
(SNP) rs4680, DRD1 rs265981, DRD2 rs6275, and DRD3
rs6280 (C__25746809_50, C__11592758_10,
C___1011775_20, C___2601173_20, and C____949770_10)
TaqMan assays were from Applied Biosystems/Fisher Scien-
tific (Foster City, CA). Genotyping assays were performed
and analyzed according to the manufacturer’s recommenda-
tions. Five-lL reactions in 384-well plates were prepared
using Eppendorf epMotion 5070 (Eppendorf North America,
Inc., Westbury, NY) liquid-handling and sample-processing
robotics. Genotype accuracy was verified by genotyping 5%
to 10% randomly selected duplicate samples for each SNP
and Hardy-Weinberg analysis. Genotyping was performed at
the University of Florida Center for Pharmacogenomics Gen-
otyping Core Laboratory.
SNPs and their anticipated effects on the dopaminer-
gic system are outlined in Table 1. COMT is an enzyme
that metabolizes dopamine and other monoamines. The
methionine (Met) allele of rs4680 is less efficient at pro-
ducing COMT and, consequently, is associated with
slower clearance and higher levels of dopamine than the
valine (Val) allele.20 The DRD1s are involved in the dopa-
minergic direct pathways, with more receptors leading to
greater signaling along these pathways.11 The DRD1
rs265981 Met allele leads to lower receptor density, lower
dopaminergic signaling, and consequently, lower dopa-
mine activity than the Val allele.14,21 The DRD2s are pre-
and postsynaptic and act in a self-regulating manner.11
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The Met allele of DRD2 rs6275 is associated with lower
receptor density, less self-modulating presynaptic activity,
and therefore, higher dopamine activity.14 Finally, DRD3s
are part of the D2 family and are located primarily in the
limbic system. The glycine (Gly) allele in the DRD3 vari-
ant rs6280 demonstrates has an affinity for dopamine
binding that is 5 times as strong as that of the serine (Ser)
allele,22 resulting in lower dopaminergic activity.
PA Monitoring
Participants were to wear an accelerometer (GT3X, Acti-
graph, Pensacola, FL) on their right hip for 7 consecutive
days before randomization and 6-, 12-, and 24-month fol-
low-up visits. Participants were to remove the device only
for sleeping and water activities. Activity during structured
PA intervention visits was not recorded. Movement was
captured along the vertical axis in 1-minute epochs, and
nonwear time was defined as 90 minutes of consecutive 0
counts.23 Analyses were limited to participants with wear
time of at least 600 min/d for 3 or more days (mean daily
minutes of wear time at each visit ranged from
812.8693.3 to 833.86109.5, and mean valid days at each
visit ranged from 6.562.4 to 7.863.5).
Dependent Variable—PA
The dependent variable was total minutes per day of mod-
erate to vigorous PA (MVPA), defined as time at or above
760 counts per minute24 according to accelerometry.
Because meaningful cut-points are established for older
adults with physical function limitations, sensitivity analy-
ses considered alternate cut-points of 500 counts per
minute, 1,041 counts per minute, and 1,500 counts per
minute. Differences in associations using different cut-
points did not change the interpretation of results (data
not shown).
Covariates
Race was self-reported at baseline. Dopamine-related SNP
alleles distributions differ according to race, and PA levels
may differ according to race, so all analyses were a priori
stratified according to black and white race to avoid con-
founding. Other races had samples too small to conduct
stratified analyses and were therefore excluded.
Age, sex, and highest education level were self-
reported at baseline. Body mass index (BMI) was calcu-
lated in kg/m2 using standard measurements for height
and weight. History of cardiovascular disease and diabetes
were self-reported. Blood pressure was measured at the
upper arm using a standard seated protocol. Intervention
adherence was calculated as percentage of sessions
attended.
Mobility limitations were measured according to
time to walk 400 m at usual pace.25 The SPPB consists of
3 components measuring lower extremity performance:
balance in side-by-side, semitandem, and tandem posi-
tions; 4-m usual-pace gait speed; and 5 repeated chair
stands.26 Each component is assigned a score from 0
(unable to complete) to 4 (best performance) and
summed to a total score of 0 to 12. We also considered
gait speed (m/s) alone. Global cognitive function was
assessed using the 3MS.27 Composite executive function
included average normalized scores from the n-back,
task-switching, and Flanker tests.28 Depressive symptoms
were assessed using the Center for Epidemiologic Studies
Depression Scale.29
The dopaminergic system modulates executive func-
tion, gait speed, and mood,7,8,10 which PA can modify,30–32
so changes in these measures were examined as explanatory
factors for the association between genotype and PA.
Statistical analyses
Raw minutes of MVPA with standard errors were plotted
according to study visit and genotype. Raw values were
skewed, so root-transformed values of minutes per day of
MVPA were used for statistical comparisons. Linear and
quadratic models did not fit the shape of the MVPA
changes over time, so we used an average value of the
transformed MVPA calculated for each participant from
baseline to 24 months. Effects of interactions between
genotype and arm on average MVPA were tested using lin-
ear regression. For genotypes with suggested interactions
(p<.2), linear regressions of arm and MVPA were con-
ducted stratified according to genotype.
Pairwise comparisons of MVPA according to genotype
within the PA arm were conducted using t-tests. False dis-
covery rate adjustment was used to account for multiple
comparisons of multiple genes. For genotypes that were
significantly associated with MVPA, we assessed bivariate
associations between genotype and potential explanatory
factors in the covariate section above. Comparisons were
Table 1. Dopamine-Related Single Nucleotide Polymorphisms and Their Hypothesized Effects on the Dopaminergic
System
Gene Variant Allele Effect on Dopaminergic System
Effect on Dopamine
Synaptic Levels or Signaling
Relative to Alternate Allele
Catechol-O-methyltransferase rs4680 Met Slower metabolism of dopamine Higher
DRD1 rs265981 Met Lower DRD1 expression Lower
DRD2 rs6275 Met Lower DRD2 expression, lower inhibitory feedback Higher
DRD3 rs6280 Glycine Higher binding affinity, lower transmission Lower
DR 5 dopamine receptor; Met 5 methionine.
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conducted using analysis of variance for continuous varia-
bles and the chi-square test for categorical variables. Lin-
ear regression models were then used to assess the
association between genotype and average log-transformed
MVPA, with adjustment for basic demographic character-
istics (age, sex, clinic site) and for covariates associated
with genotype in bivariate analyses at p<.1. We decided a
priori to adjust for changes in gait speed, executive func-
tion, and depressive symptoms over 24 months. All analy-
ses were conducted in 2017 using SAS version 9.4 (SAS
Institute, Inc., Cary, NC).
RESULTS
The analytical sample had a mean age of 78.865.2;
20.0% were black, and 64.9% were female.
Interactions between study arm and DRD2 (p5.18) or
COMT (p5.12) genotype were suggestive of a differential
intervention effect according to genotype in white partici-
pants. Mean between-arm differences in MVPA were
larger for those with the DRD2 Met/Met genotype (HE:
4.7661.80, PA: 5.5361.60, p5.03) than for those with
the Met/Val (HE: 4.3861.70, PA: 4.8762.04, p5.01) or
Val/Val genotype (HE: 4.5861.92, PA: 4.8161.83,
p5.16). Similarly, between-arm differences in MVPA were
larger for those with the COMT Met/Met genotype (HE:
4.3161.79, PA: 5.0761.83, p5.001) than for those with
the Met/Val (HE: 4.5661.83, PA: 4.8861.96, p5.06) or
Val/Val genotype (HE: 4.7461.89, PA: 4.0961.21,
p5.68).
Raw minutes of PA are shown according to genotype
for white participants in the PA arm (n5513) in Figure 1
(data in Supplemental Table S2). There were no baseline
differences in PA according to genotype (all p>.1; Table 2).
There were significant associations between DRD2 geno-
type and average MVPA (Table S2). Participants with the
Met/Met DRD2 genotype had higher levels of MVPA than
those with the Met/Val (p5.01) and Val/Val genotypes
(p5.01). No other genotypes were significantly associated
with average MVPA (Table 2).
Of the covariates assessed, there was a trend for an
association only with history of cardiovascular disease
with DRD2 genotype (p5.09; Supplemental Table S3).
There were also trends toward maintenance of gait speed
in Met/Met genotype, whereas there were declines in the
other genotypes (p5.14). Similarly, there was a trend
toward improvement in depressive symptoms for the Met/
Met genotype but no change in other genotypes (p5.18;
Supplemental Table S3). Regression models of the DRD2
genotype with the average square root minutes of MVPA
per day were largely robust to adjustment for basic demo-
graphic characteristics or cardiovascular disease, although
adjustment for demographic characteristics slightly attenu-



























































Figure 1. Median (standard error) minutes of moderate to vigorous physical activity (MVPA) per day according to time period
for whites in the physical activity arm of the Lifestyle Interventions and Independence for Elders Study (N5513) according to
genotype: (A) catechol-O-methyltransferase, (B) dopamine receptor (DR)D1, (C) DRD2, and (D) DRD3. A solid line indicates
the genotype associated with the highest dopamine signaling, and a short dashed line indicates the lowest dopamine signaling.
The long dashed line indicates heterozygotes.
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(Table 3). Adjustment for either in executive function or
in depressive symptoms did not alter the results, although
adjustment for change in gait speed partially attenuated
the difference for the Met/Val and Val/Val genotypes rela-
tive to the Met/Met genotype (Table 3).
There were no significant associations observed for
black participants (Supplemental Tables S4 and S5).
DISCUSSION
In an intervention study of older adults at risk of mobility
disability, polymorphisms in the DRD2 and COMT genes
related to higher dopamine signaling, compared to poly-
morphisms related to lower dopamine signaling, were
associated with greater increases in MVPA in the PA than
the HE arm. Furthermore, the DRD2 Met/Met genotype
was associated with greater change in MVPA in the PA
arm than the Met/Val and Val/Val genotypes. Demo-
graphic and health characteristics, which largely did not
differ according to genotype, did not explain these differ-
ences. Changes in executive function or mood during the
intervention did not explain these differences, but changes
in gait speed attenuated them somewhat. Differences in
PA according to DRD2 genotype were not evident at base-
line, and polymorphisms in COMT, DRD1, and DRD3
genes were not related to MVPA changes in the PA arm.
Moreover, the effect was observed for white but not black
participants.
The Met allele of the rs6275 SNP is associated with
less DRD2 receptor density, resulting in less autoregulat-
ing presynaptic activity and higher dopamine signalling.14
The Met/Met homozygotes had greater average MVPA
during the intervention than the Val/Val and Met/Val
genotypes, but there were no differences at baseline.
Table 3. Linear Regression of Average Square Root Minutes of Moderate to Vigorous Physical Activity (MVPA)
per Day from Baseline to 24 Months According to Genotype for White Participants in the Physical Activity Arm of
the Lifestyle Interventions and Independence for Elders Study
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Genotype (reference Met/Met) b, P-Value
Val/Val –0.72, 0.02 –0.66, 0.02 –0.77, 0.01 –0.56, 0.05 –0.79, 0.01 –0.79, 0.01
Met/Val –0.66, 0.03 –0.50, 0.08 –0.67, 0.02 –0.54, 0.06 –0.70, 0.03 –0.76, 0.02
Model 1: unadjusted.
Model 2: adjusted for clinical site, age, sex.
Model 3: adjusted for history of cardiovascular disease.
Model 4: adjusted for change in gait speed over 24 months.
Model 5: adjusted for change in executive function over 24 months.
Model 6: adjusted for change in Center for Epidemiologic Studies Depression Scale score.
Val 5 valine; Met 5 methionine.
Table 2. Pairwise Comparisons of Average Square Root Minutes of Moderate to Vigorous Physical Activity
(MVPA) per Day (Baseline To 24 Months) for White Participants in the Physical Activity Arm of the Lifestyle
Interventions and Independence for Elders Study (N 5 513)
Val/Val Met/Val Met/Met Val/Val vs Met/Val Val/Val vs Met/Met Met/Val vs Met/Met
Gene Mean 6 Standard Deviation P-Value
Catechol-O-methyltransferase n 5 118 n 5 254 n 5 141
Baseline MVPA 4.43 6 1.90 4.77 6 2.09 4.73 6 1.97 .27 .75 .77
Average MVPA 4.52 6 2.70 4.58 6 2.51 4.77 6 2.34 .17 .80 .77
DRD11 n 5 211 n 5 228 n 5 71
Baseline MVPA 4.73 6 1.91 4.67 6 2.09 4.66 6 2.13 .67 .73 .94
Average MVPA 4.77 6 2.48 4.55 6 2.59 4.75 6 2.89 .63 .99 .99
DRD2 n 5 248 n 5 215 n 5 50
Baseline MVPA 4.61 6 1.95 4.71 6 2.11 5.06 6 1.94 .71 .16 .30
Average MVPA 4.65 6 2.71 4.46 6 2.51 5.39 6 2.00 .91 .01 .01
Ser/Sera Ser/Glyb Gly/Glyc Ser/Ser vs Ser/Gly Ser/Ser vs Gly/Gly Ser/Gly vs Gly/Gly
DRD31 n 5 41 n 5 239 n 5 228
Baseline MVPA 4.51 6 2.48 4.69 6 1.99 4.73 6 1.96 .11 .97 .64
Average MVPA 4.42 6 3.15 4.65 6 2.43 4.73 6 2.51 .24 .83 .83
p-values are false discovery rate adjusted to account for multiple comparisons.
1Data were missing for 3 in the dopamine receptor (DR)D1 genotype group and 5 in the DRD3 genotype group.
Val 5 valine; Met 5 methionine; Ser 5 serine; Gly 5 glycine.
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DRD2 receptors are primarily located within the basal
ganglia and are involved in reward11 and motor control.33
Positron emission studies have shown that DRD2 binding
increases after acute bouts of exercise in individuals with
Parkinson’s disease34 and in methamphetamine users.35
These results were not observed in young, healthy individ-
uals,36 suggesting that exercise-induced increases in DRD2
binding occurs only in those with disease-related or phar-
macologically induced changes in dopaminergic neuro-
transmission. Dopaminergic function declines with age,8
but whether these declines alter DRD2 binding in response
to acute bouts of exercise is untested. It is also unknown
whether D2 receptor density as determined according to
genotype may alter D2 binding response to exercise or
whether these acute changes in binding potential have
long-term consequences for maintenance of PA.
We further found that that changes in gait speed par-
tially attenuated the association between DRD2 and
MVPA. We were unable to determine the direction of this
association; higher PA could lead to better maintenance of
gait speed, or greater maintenance of gait speed could
allow for greater PA participation.37 Finally, we found
associations in white but not black participants. It is
unclear why, although this is consistent with a prior study
that found associations between DRD2 and PA only in
white individuals.16 We had a small sample of black par-
ticipants, and although the results were not significant,
they were in a consistent direction with those for white
participants, indicating that the lack of significant results
is because of limited power. In addition, black individuals
may experience more barriers to PA participation,38 which
could eclipse the effects of a single gene.
To our knowledge, this is the first study to examine
dopamine-related genotypes in relation to changes in PA
during an intervention. Studies13–16 of dopaminergic geno-
types and PA have been observational and relied on self-
reported PA. Only one prior study identified an association
between DRD2 and amount of PA.16 Others were unable
to replicate this finding or identify associations between
other dopamine-related genotypes and PA.13–15 The lack of
association between DRD2 genotype and PA levels in our
baseline data confirm these prior negative findings. The
effects of a single genotype on a complex behavior such as
PA are expected to be small, and other behavioral and envi-
ronmental influences may overshadow them, but with a PA
intervention that involves scheduled, center-based activity
with a social group of peers and access to trainers, many of
the behavioral and environmental barriers are removed,
and the effect of genotype may be more evident. Evidence
from intervention trials for neurobiological drivers of PA
participation is limited. Two recent studies39,40 in older
adults have identified grey matter regions related to greater
intervention-related exercise class attendance. Both studies
identified greater volumes of portions of the prefrontal,
parietal, and temporal cortices as important correlates of
higher attendance. One study identified greater volume of
the basal ganglia, site of DRD2s, as being predictive of
greater attendance,40 but the other did not.39 Neither of
these studies assessed objectively measured PA levels, and
no prior studies have assessed neurotransmitter involvement
in PA during an intervention.
Our study had several limitations, including small sam-
ple sizes in nonwhite participants. In addition, we lacked
power to examine interactions with sex; sex hormones have
known effects on dopaminergic function.41 We hypothe-
sized that one potential pathway would be through motiva-
tion and reward pathways, but we had no measures to test
this hypothesis. Finally, we were limited in our measure-
ment of dopaminergic integrity to four genotypes; we did
not have direct measures of dopaminergic function, did not
test all possible genes related to dopamine, and did not
examine interactions between genes.
Our study also had several strengths. Participants
came from a rigorous intervention study in which
center-based exercise classes were offered that were cus-
tomized to the individual and were conducted in group
settings with peer support. This may have reduced the
barriers to PA participation, allowing the small effects
of genotypes to become evident. In addition, we had
objectively measured PA assessments using accelerome-
try, which reduced the likelihood of misclassification
from self-report.
CONCLUSIONS
There is growing interest in understanding neurobiological
drivers of PA participation, particularly in older adults.
There is strong biological plausibility for involvement of
the dopaminergic system in driving PA, but there has been
little evidence from population studies to confirm this
role. Although genotypes are not modifiable, and these
results are preliminary, they indicate a potential role for
the dopaminergic system in PA for older adults in the set-
ting of a structured intervention. Future studies should
include direct measurement of dopamine levels using posi-
tron emission tomography to explore further the role of
dopamine in intervention response. By further understand-
ing this mechanism, we may be able to develop methods
to harness the dopaminergic system, including individual-
ized pharmacotherapy, to increase and maintain PA partic-
ipation in older adults.
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